Isis Pharma Posts Positive Phase 1 Data on Three Drugs in Development to Treat Metabolic Disorders
Posted on December 07, 2012 at 08:03 AM EST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) announced today positive results from Phase 1 studies of three drugs, ISIS-PTP1B[Rx], ISIS-GCGR[Rx] and ISIS-GCCR[Rx], in development to treat metabolic disorders, including type 2 diabetes. In all three Phase 1 studies, the drugs were safe and well tolerated with early encouraging data that supports the unique mechanism of